Gail Boxer Marcus sold $2.4M of NTRA
director at Natera, Inc.. 11,000 shares at an average of $217.21, traded Jun 5, 2026, filed Jun 9, 2026.
Score components
- +15RoleDirector
- +25Trade size$2.4M at market
- +20Share of holdings soldSold 64% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001702176-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | MOption exercise Common Stock | +11,000 | $22.83 | $251k | 17,183 | Jun 9, 2026 |
| Jun 5, 2026 | SOpen-market sale Common Stock | -3,016 | $216.06 | $652k | 14,167 | Jun 9, 2026 |
| Jun 5, 2026 | SOpen-market sale Common Stock | -4,694 | $217.30 | $1.0M | 9,473 | Jun 9, 2026 |
| Jun 5, 2026 | SOpen-market sale Common Stock | -3,174 | $218.11 | $692k | 6,299 | Jun 9, 2026 |
| Jun 5, 2026 | SOpen-market sale Common Stock | -116 | $218.82 | $25k | 6,183 | Jun 9, 2026 |
| Jun 5, 2026 | MOption exercise Stock Option (right to buy)derivative | -11,000 | $0.00 | $0 | 11,000 | Jun 9, 2026 |
Related signals
Other insiders at Natera, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $526k 1,273 shares | -1% | |
| 40Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $1.2M 3,000 shares | -3% | |
| 55Moderate | Natera, Inc. | Jonathan Sheena director, other | $7.0M 18,064 shares | -100% | |
| 35Weak | Natera, Inc. | Jonathan Sheena director, other | $3.2M 9,150 shares | -4% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $35M 102,000 shares | -5% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $16M 50,000 shares | -2% | |
| 39Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $545k 1,698 shares | -2% | |
| 45Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $5.9M 18,160 shares | -14% | |
| 40Moderate | Natera, Inc. | John Fesko PRESIDENT, CHIEF BUS. OFFICER | $2.1M 6,517 shares | -3% | |
| 35Weak | Natera, Inc. | Jonathan Sheena director, other | $2.0M 6,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.